悦康药业:2025一季报净利润-0.49亿 同比下降171.01%

Financial Performance - The company reported a basic earnings per share of -0.1100 yuan for Q1 2025, a decrease of 173.33% compared to 0.1500 yuan in Q1 2024 [1] - The total revenue for Q1 2025 was 5.77 billion yuan, down 40.39% from 9.68 billion yuan in Q1 2024 [1] - The net profit for Q1 2025 was -0.49 billion yuan, representing a decline of 171.01% from a profit of 0.69 billion yuan in Q1 2024 [1] - The return on equity for Q1 2025 was -1.39%, a significant drop from 1.92% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 25,836.88 million shares, accounting for 57.42% of the circulating shares, with a decrease of 1,485.70 million shares compared to the previous period [1] - The largest shareholder, Fuyang Jingyue Yongshun Information Consulting Co., Ltd., holds 18,024.01 million shares, representing 40.05% of the total share capital, with no change [2] - Hong Kong Central Clearing Limited and China Merchants Medical Health Industry Stock have exited the top ten shareholders list [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]